Share chart Recursion Pharmaceuticals, Inc.
Extended chart
Simple chart
Main settings
Currency
usd
Dividend income of JSC
0
IPO Time
2021-04-16
ISIN
US75629V1044
Industry
Biotechnology
Report Currency
usd
Sector
Health Care
Website
Grade
Underestimation
| Title | Value | Grade |
| P/S | 31.5 | 1 |
| P/BV | 1.79 | 8 |
| P/E | -3.37 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -44.11 | 0 |
| ROE | -61.89 | 0 |
| ROIC | -127.47 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.2542 | 10 |
| Debt/Ratio | 0.0749 | 10 |
| Debt/Equity | 0.3999 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | 1370.98 | 10 |
| Ebitda, % | 425.49 | 10 |
| EPS, % | 119.6 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 4.63 $ | 0 $ | 0 $ | +1.94 % | 0 % | 0 % |
| Week | 4.91 $ | 0 $ | 0 $ | -3.87 % | 0 % | 0 % |
| Month | 4.87 $ | 4.54 $ | 4.98 $ | -2.98 % | 0 % | 0 % |
| Three month | 5.03 $ | 4.52 $ | 6.54 $ | -6.16 % | 0 % | 0 % |
| Half a year | 5.29 $ | 4.08 $ | 6.54 $ | -10.78 % | 0 % | 0 % |
| Year | 7.41 $ | 3.97 $ | 10.87 $ | -36.3 % | 0 % | 0 % |
| 3 years | 16.78 $ | 3.97 $ | 15.86 $ | -71.87 % | 0 % | 0 % |
| 5 years | 3.97 $ | 3.97 $ | 41.33 $ | +116.62 % | 0 % | 0 % |
| 10 years | 3.97 $ | 3.97 $ | 41.33 $ | +116.62 % | 0 % | 0 % |
| Year to date | 6.03 $ | 3.97 $ | 10.87 $ | -21.72 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 0.18148 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.18148 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.06084 | 519.61 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.03054 | 270.73 | 0.25 |
| 0.11 | 316.48 | 0.25 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Tina Marriott Larson | COO & President | 612.69k | 1975 (50 years) |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director | 40k | 1982 (43 years) |
| Dr. Michael Secora Ph.D. | Chief Financial Officer | 524.19k | 1983 (42 years) |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer | N/A | 1983 (42 years) |
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, CEO & Director | 695.18k | 1983 (42 years) |
| Kevin Leggat | Vice President of Finance & Accounting | N/A | |
| Mr. Jared Allenbach | Senior Director of Investor Relations | N/A | |
| Mr. Ryan Kelly | Chief Communications Officer | N/A | |
| Mr. Nathan Hatfield | Chief Legal Officer & General Counsel | N/A | |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer | 1965 (60 years) |
About company
Address: United States, Salt Lake City, 41 South Rio Grande Street - Open in google maps, Open in yandex maps
Website: http://www.recursion.com
Website: http://www.recursion.com
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. работает как биотехнологическая компания на клинической стадии, расшифровывающая биологию путем интеграции технологических инноваций в области биологии, химии, автоматизации, науки о данных и инженерии для индустриализации открытия лекарств. В нем есть четыре кандидата на клинические препараты, предназначенные для лечения редких моногенных заболеваний; и 33 дополнительных программы на разных стадиях доклинической разработки. Recursion Pharmaceuticals, Inc. имеет стратегические соглашения с Bayer; Государственный инновационный фонд Огайо; Chromaderm, Inc .; и Takeda Pharmaceutical Company Limited. Компания была основана в 2013 году и базируется в Солт-Лейк-Сити, штат Юта.
